These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26008804)

  • 1. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
    Sjöström CD; Johansson P; Ptaszynska A; List J; Johnsson E
    Diab Vasc Dis Res; 2015 Sep; 12(5):352-8. PubMed ID: 26008804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
    Weber MA; Mansfield TA; Alessi F; Iqbal N; Parikh S; Ptaszynska A
    Blood Press; 2016; 25(2):93-103. PubMed ID: 26623980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
    Heerspink HJ; Johnsson E; Gause-Nilsson I; Cain VA; Sjöström CD
    Diabetes Obes Metab; 2016 Jun; 18(6):590-7. PubMed ID: 26936519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
    Ott C; Jumar A; Striepe K; Friedrich S; Karg MV; Bramlage P; Schmieder RE
    Cardiovasc Diabetol; 2017 Feb; 16(1):26. PubMed ID: 28231831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
    Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
    J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
    Grandy S; Hashemi M; Langkilde AM; Parikh S; Sjöström CD
    Diabetes Obes Metab; 2014 Jul; 16(7):645-50. PubMed ID: 24443876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
    Brown RE; Gupta N; Aronson R
    Diabetes Technol Ther; 2017 Nov; 19(11):685-691. PubMed ID: 28829163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
    Yang W; Ji L; Zhou Z; Cain VA; Johnsson KM; Sjöström CD
    J Diabetes; 2017 Aug; 9(8):787-799. PubMed ID: 27625142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
    Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
    Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.
    Grandy S; Langkilde AM; Sugg JE; Parikh S; Sjöström CD
    Int J Clin Pract; 2014 Apr; 68(4):486-94. PubMed ID: 24499168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
    Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
    Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
    Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
    Fioretto P; Del Prato S; Buse JB; Goldenberg R; Giorgino F; Reyner D; Langkilde AM; Sjöström CD; Sartipy P;
    Diabetes Obes Metab; 2018 Nov; 20(11):2532-2540. PubMed ID: 29888547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
    Heerspink HJL; Sjöström CD; Inzucchi SE; Hallow MK; Cain VA; Rossing P; Stefansson BV; Sartipy P
    Diabetes Obes Metab; 2019 Mar; 21(3):720-725. PubMed ID: 30414240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
    Kohan DE; Fioretto P; Tang W; List JF
    Kidney Int; 2014 Apr; 85(4):962-71. PubMed ID: 24067431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
    Papadopoulou E; Loutradis C; Tzatzagou G; Kotsa K; Zografou I; Minopoulou I; Theodorakopoulou MP; Tsapas A; Karagiannis A; Sarafidis P
    J Hypertens; 2021 Apr; 39(4):749-758. PubMed ID: 33186325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
    Sjöström CD; Hashemi M; Sugg J; Ptaszynska A; Johnsson E
    Diabetes Obes Metab; 2015 Aug; 17(8):809-12. PubMed ID: 25997813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.